ArticleBritish journal of cancer2011

Comment on 'Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab'.

H Shimokawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.